Advancing Science. Improving Connections.

Next-generation transdermal cannabinoid therapeutics to improve the lives of patients affected by rare and near-rare neuropsychiatric conditions.

Our Patients

Focusing on the unmet medical needs of patients with rare disorders and their families

More

Our Company

Progressing our mission to improve the lives of patients battling certain rare and near-rare diseases

More

Our Pipeline

Pioneering cannabinoid treatments for neuropsychiatric conditions

More

Latest News

02.20

Zynerba Pharmaceuticals Appoints Pamela Stephenson to Board of Directors

Read More
02.05

Zynerba Pharmaceuticals to Present at the 2019 BIO CEO and Investor Conference

Read More
12.17

Zynerba Pharmaceuticals Provides Clinical Update and Announces Two New Clinical Indications

Read More
12.12

Zynerba Pharmaceuticals Announces Sustained Improvements in Emotional and Behavioral Symptoms of Fragile X Syndrome through 12 Months of Treatment with ZYN002

Read More

This site uses cookies to give you a better browsing experience. By continuing to use this website, you accept our use of these cookies. For more information, see our Privacy Notice.